Recent Quotes (30 days)

You have no recent quotes
chg | %

Sophiris Bio Inc  

(Public, TSE:SHS)   Watch this stock  
Find more results for SHS
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 4.25 - 18.20
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -4.35
Shares     -
Beta     -
Inst. own     -
Aug 7, 2015
Q2 2015 Sophiris Bio Inc Earnings Release (Estimated)

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -85.24% -79.27%
Return on average equity -169.73% -111.75%
Employees 9 -
CDP Score - -


1258 Prospect Street
LA JOLLA, CA 92037
United States - Map
+1-858-7771760 (Phone)
+1-858-4125693 (Fax)

Website links


Sophiris Bio Inc. is a clinical-stage biopharmaceutical company focused on developing products for the treatment of urological diseases. The Company is involved in the development of PRX302, which is used for treatment of the symptoms of benign prostatic hyperplasia and referred to as an enlarged prostate. PRX302 is a genetically modified recombinant protein that is delivered through ultrasound-guided injection directly into the prostate. It is delivered through a targeted injection into the prostate, ablating the prostate tissue without damaging neighboring tissue and nerves. This method of administration limits the circulation of the drug in the body. The Company holds commercial rights of PRX302 in markets, including, Canada, the United States, Europe and Asia (except Japan).

Officers and directors

Lars G. Ekman Chairman of the Board
Age: 65
Randall E. Woods President, Chief Executive Officer, Director
Age: 63
Peter T. Slover CPA Chief Financial Officer
Age: 40
Allison J. Hulme Ph.D. Chief Operating Officer, Head - Research & Development
Age: 52
John Geltosky Ph.D. Independent Director
Age: 69
James L. Heppell Independent Director
Age: 59
Gerald T. Proehl Independent Director
Age: 56
Joseph L. Turner Jr. Independent Director
Age: 63